Yahoo! Finance: Biotechnology Industry News: Exelixis Presents COMETRIQ™ (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

Exelixis Presents COMETRIQ™ (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer Jun 2nd 2013, 13:00 [Business Wire] - Exelixis, Inc. today announced the presentation of additional data from clinical trials of COMETRIQ™ in patients with progressive, metastatic medullary thyroid cancer .

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions